ArticleCureus2026
Impact of Blood Herpes Simplex Virus Polymerase Chain Reaction Testing in Neonatal Management of Herpes Simplex Virus Infection: An Institutional Experience.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe evaluation of neonatal herpes simplex virus (HSV) includes HSV culture and/or polymerase chain reaction (PCR) of different surfaces, cerebrospinal fluid (CSF), and blood. However, the impact of blood HSV PCR for the management of neonatal HSV infections has not been well-established.
objectiveTo evaluate the impact of blood HSV PCR results in the management (i.e., clinical decision-making regarding treatment) of neonatal HSV infections at our institution, where this test is performed at an outside facility.
methodsWe retrospectively reviewed the medical records of all neonates tested for HSV DNA in blood from January 1, 2018, to July 31, 2023, at our children's hospital.
resultsA total of 149 medical records were analyzed, of which seven had positive blood HSV PCR. These seven patients and five of 142 patients with negative blood HSV PCR had a positive HSV PCR result from another site, and they were managed according to those results. The mean turnaround time (TAT) for the results of blood HSV PCR was three and a half days for positive results and four days for negative results. In most patients with negative PCR from other sites, including CSF, acyclovir was discontinued before the blood HSV PCR results were back. Acyclovir was not discontinued until the results were available in only 12 of 134 neonates who had all negative results and available information about management. Statistical analysis showed that blood HSV PCR did not significantly impact the management of these neonates. Conclusions: Our study does not support the use of blood HSV PCR in the evaluation of neonatal HSV infection specifically in institutions where the test is not performed in-house, because the test results are not available in a timely fashion to have an impact on the management of these neonates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.